News

FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label

FDA · lung cancer · 6 min

FDA approves Merck’s Keytruda for adjuvant NSCLC treatment

FDA · lung cancer · 8 min

Eli Lilly's donanemab wins FDA approval for early Alzheimer's disease

FDA · Alzheimer's disease · 6 min

FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst

FDA · lung cancer · 7 min

FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer

FDA · oncology · 7 min

FDA approves Keytruda adjuvant NSCLC use: what Merck investors should watch

FDA · oncology · 7 min

Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst

EMA · oncology · 5 min

Triple Hormone-Receptor Agonist Retatrutide for Obesity: Phase 3 Results and Market Impact

obesity · 4 min

Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know

FDA · gene therapy · 4 min

Johnson And Johnson ASCO 2026 Data Adds Depth To JNJ Valuation Story

oncology · 4 min

Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook

obesity · 4 min

Puma Biotechnology Inducement Awards: Strategic Talent Moves Under Nasdaq Rule 5635(c)(4)

Nasdaq · 4 min